Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (US FDA) to market Febuxostat Tablets, 40 mg and 80 mg (USRLD: Uloric Tablets).

Indoco Remedies on Tuesday said it has got final approval from the US health regulator for Febuxostat tablets used for the treatment of gout caused by excessive levels of uric acid in the blood. The ...

Global pharma major Lupin Limited (Lupin) on Thursday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application ...

Aurobindo has received the Food and Drug Administration’s permission for febuxostat tablets, 40 mg and 80 mg, which are the generic of Takeda’s Uloric. Febuxostat tablets are indicated for the chronic ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr.

Drug firm Alembic Pharmaceuticals Tuesday said it has received approval from the US health regulator for Febuxostat tablets, used to lower high levels of uric acid in adults who have gout. The ...

Indoco Remedies received final approval of its Abbreviated new drug application (ANDA) for febuxostat tablets 40 mg and 80 mg from US Food and Drug Administration (FDA), which is therapeutically ...

Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 05, 2016 titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Febuxostat Tablets".Source : BSE ...

New Delhi: Indoco Remedies on Tuesday said it has got final approval from the US health regulator for Febuxostat tablets used for the treatment of gout caused by excessive levels of uric acid in the ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr.

Shares of Sun Pharma Advanced Research Company (SPARC) rallied as much as 7.24 per cent after it informed bourses that the company and Sun Pharmaceutical have entered into a licensing arrangement for ...